Accessibility StatementSkip Navigation Updated results from the Phase 3 EMBER-3 trial for Inluriyoâ"¢ (imlunestrant) alone and in combination with Verzenio (abemaciclib) in ER+, HER2– metastatic breast cancer to be presented as a late-breaking oral presentation Updated safety and efficacy data to be presented from PIKALO-1, the Phase 1/2 trial of Lilly's pan-mutant- selective PI3K inhibitor, which will be advanced into the Phase 3 PIKALO-2 study New subgroup analysis from the Phase 3 monarchE trial that exp ...